JP2018514202A - 遺伝子融合体を検出するための多重pcr - Google Patents
遺伝子融合体を検出するための多重pcr Download PDFInfo
- Publication number
- JP2018514202A JP2018514202A JP2017554014A JP2017554014A JP2018514202A JP 2018514202 A JP2018514202 A JP 2018514202A JP 2017554014 A JP2017554014 A JP 2017554014A JP 2017554014 A JP2017554014 A JP 2017554014A JP 2018514202 A JP2018514202 A JP 2018514202A
- Authority
- JP
- Japan
- Prior art keywords
- gene
- primer
- fusion
- primer pair
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000004927 fusion Effects 0.000 title claims abstract description 172
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 145
- 238000007403 mPCR Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 49
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 230000003321 amplification Effects 0.000 claims description 55
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 55
- 230000002441 reversible effect Effects 0.000 claims description 34
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 239000012472 biological sample Substances 0.000 claims description 19
- 239000002773 nucleotide Substances 0.000 claims description 17
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 11
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 11
- 108020004414 DNA Proteins 0.000 claims description 10
- 101001050559 Homo sapiens Kinesin-1 heavy chain Proteins 0.000 claims description 10
- 102100023422 Kinesin-1 heavy chain Human genes 0.000 claims description 10
- 102100027100 Echinoderm microtubule-associated protein-like 4 Human genes 0.000 claims description 9
- 101001057929 Homo sapiens Echinoderm microtubule-associated protein-like 4 Proteins 0.000 claims description 9
- 102100034343 Integrase Human genes 0.000 claims description 9
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 9
- 102100031048 Coiled-coil domain-containing protein 6 Human genes 0.000 claims description 7
- 101000777370 Homo sapiens Coiled-coil domain-containing protein 6 Proteins 0.000 claims description 7
- 108091008794 FGF receptors Proteins 0.000 claims description 6
- 238000003757 reverse transcription PCR Methods 0.000 claims description 6
- 101000783817 Agaricus bisporus lectin Proteins 0.000 claims description 5
- 101001021527 Homo sapiens Huntingtin-interacting protein 1 Proteins 0.000 claims description 5
- 101000605496 Homo sapiens Kinesin light chain 1 Proteins 0.000 claims description 5
- 101000588130 Homo sapiens Microsomal triglyceride transfer protein large subunit Proteins 0.000 claims description 5
- 101000800847 Homo sapiens Protein TFG Proteins 0.000 claims description 5
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 5
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 claims description 5
- 102100035957 Huntingtin-interacting protein 1 Human genes 0.000 claims description 5
- 102100038306 Kinesin light chain 1 Human genes 0.000 claims description 5
- 102100033661 Protein TFG Human genes 0.000 claims description 5
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 5
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 claims description 5
- 102100029505 E3 ubiquitin-protein ligase TRIM33 Human genes 0.000 claims description 4
- 101000634991 Homo sapiens E3 ubiquitin-protein ligase TRIM33 Proteins 0.000 claims description 4
- 101000974343 Homo sapiens Nuclear receptor coactivator 4 Proteins 0.000 claims description 4
- 102100022927 Nuclear receptor coactivator 4 Human genes 0.000 claims description 4
- 239000013068 control sample Substances 0.000 claims 2
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims 2
- 230000000977 initiatory effect Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 27
- 201000011510 cancer Diseases 0.000 abstract description 17
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 50
- 239000000523 sample Substances 0.000 description 36
- 150000007523 nucleic acids Chemical class 0.000 description 34
- 102000039446 nucleic acids Human genes 0.000 description 30
- 108020004707 nucleic acids Proteins 0.000 description 30
- 238000011282 treatment Methods 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 20
- 238000001514 detection method Methods 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 15
- 108091033319 polynucleotide Proteins 0.000 description 13
- 239000002157 polynucleotide Substances 0.000 description 13
- 102000040430 polynucleotide Human genes 0.000 description 13
- 238000011529 RT qPCR Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 11
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 11
- -1 GADPH Proteins 0.000 description 10
- 238000001574 biopsy Methods 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000000975 dye Substances 0.000 description 8
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 7
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 4
- 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 description 4
- 108010088350 Lactate Dehydrogenase 5 Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 4
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 241000589596 Thermus Species 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 3
- 229960005061 crizotinib Drugs 0.000 description 3
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical compound NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 2
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- UDGUGZTYGWUUSG-UHFFFAOYSA-N 4-[4-[[2,5-dimethoxy-4-[(4-nitrophenyl)diazenyl]phenyl]diazenyl]-n-methylanilino]butanoic acid Chemical compound COC=1C=C(N=NC=2C=CC(=CC=2)N(C)CCCC(O)=O)C(OC)=CC=1N=NC1=CC=C([N+]([O-])=O)C=C1 UDGUGZTYGWUUSG-UHFFFAOYSA-N 0.000 description 2
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 2
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 2
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 2
- WQZIDRAQTRIQDX-UHFFFAOYSA-N 6-carboxy-x-rhodamine Chemical compound OC(=O)C1=CC=C(C([O-])=O)C=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 WQZIDRAQTRIQDX-UHFFFAOYSA-N 0.000 description 2
- JBNOVHJXQSHGRL-UHFFFAOYSA-N 7-amino-4-(trifluoromethyl)coumarin Chemical compound FC(F)(F)C1=CC(=O)OC2=CC(N)=CC=C21 JBNOVHJXQSHGRL-UHFFFAOYSA-N 0.000 description 2
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 102100021699 Eukaryotic translation initiation factor 3 subunit B Human genes 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 101000896557 Homo sapiens Eukaryotic translation initiation factor 3 subunit B Proteins 0.000 description 2
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 2
- 101000741800 Homo sapiens Peptidyl-prolyl cis-trans isomerase H Proteins 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 102100038827 Peptidyl-prolyl cis-trans isomerase H Human genes 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 241000204664 Thermotoga neapolitana Species 0.000 description 2
- 241000589499 Thermus thermophilus Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229950004272 brigatinib Drugs 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- VYXSBFYARXAAKO-UHFFFAOYSA-N ethyl 2-[3-(ethylamino)-6-ethylimino-2,7-dimethylxanthen-9-yl]benzoate;hydron;chloride Chemical compound [Cl-].C1=2C=C(C)C(NCC)=CC=2OC2=CC(=[NH+]CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000007837 multiplex assay Methods 0.000 description 2
- HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000012925 reference material Substances 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 108010002164 tyrosine receptor Proteins 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 229960000241 vandetanib Drugs 0.000 description 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 2
- GIANIJCPTPUNBA-QMMMGPOBSA-N (2s)-3-(4-hydroxyphenyl)-2-nitramidopropanoic acid Chemical compound [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=C(O)C=C1 GIANIJCPTPUNBA-QMMMGPOBSA-N 0.000 description 1
- DUFUXAHBRPMOFG-UHFFFAOYSA-N 1-(4-anilinonaphthalen-1-yl)pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C(C1=CC=CC=C11)=CC=C1NC1=CC=CC=C1 DUFUXAHBRPMOFG-UHFFFAOYSA-N 0.000 description 1
- ZTTARJIAPRWUHH-UHFFFAOYSA-N 1-isothiocyanatoacridine Chemical compound C1=CC=C2C=C3C(N=C=S)=CC=CC3=NC2=C1 ZTTARJIAPRWUHH-UHFFFAOYSA-N 0.000 description 1
- RUDINRUXCKIXAJ-UHFFFAOYSA-N 2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,14-heptacosafluorotetradecanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F RUDINRUXCKIXAJ-UHFFFAOYSA-N 0.000 description 1
- NSMMFSKPGXCMOE-UHFFFAOYSA-N 2-[2-(2-sulfophenyl)ethenyl]benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1C=CC1=CC=CC=C1S(O)(=O)=O NSMMFSKPGXCMOE-UHFFFAOYSA-N 0.000 description 1
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 1
- HZTYDQRUAWIZRE-UHFFFAOYSA-N 2-[[2-[[1-[2-(dimethylamino)-1-oxoethyl]-5-methoxy-2,3-dihydroindol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methylbenzamide Chemical compound CNC(=O)C1=C(F)C=CC=C1NC1=C2C=CN=C2NC(NC=2C(=CC=3CCN(C=3C=2)C(=O)CN(C)C)OC)=N1 HZTYDQRUAWIZRE-UHFFFAOYSA-N 0.000 description 1
- LAXVMANLDGWYJP-UHFFFAOYSA-N 2-amino-5-(2-aminoethyl)naphthalene-1-sulfonic acid Chemical compound NC1=CC=C2C(CCN)=CC=CC2=C1S(O)(=O)=O LAXVMANLDGWYJP-UHFFFAOYSA-N 0.000 description 1
- CPBJMKMKNCRKQB-UHFFFAOYSA-N 3,3-bis(4-hydroxy-3-methylphenyl)-2-benzofuran-1-one Chemical compound C1=C(O)C(C)=CC(C2(C3=CC=CC=C3C(=O)O2)C=2C=C(C)C(O)=CC=2)=C1 CPBJMKMKNCRKQB-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- YSCNMFDFYJUPEF-OWOJBTEDSA-N 4,4'-diisothiocyano-trans-stilbene-2,2'-disulfonic acid Chemical compound OS(=O)(=O)C1=CC(N=C=S)=CC=C1\C=C\C1=CC=C(N=C=S)C=C1S(O)(=O)=O YSCNMFDFYJUPEF-OWOJBTEDSA-N 0.000 description 1
- OSWZKAVBSQAVFI-UHFFFAOYSA-N 4-[(4-isothiocyanatophenyl)diazenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(N=C=S)C=C1 OSWZKAVBSQAVFI-UHFFFAOYSA-N 0.000 description 1
- SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 description 1
- ZWONWYNZSWOYQC-UHFFFAOYSA-N 5-benzamido-3-[[5-[[4-chloro-6-(4-sulfoanilino)-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]diazenyl]-4-hydroxynaphthalene-2,7-disulfonic acid Chemical compound OC1=C(N=NC2=CC(NC3=NC(NC4=CC=C(C=C4)S(O)(=O)=O)=NC(Cl)=N3)=CC=C2S(O)(=O)=O)C(=CC2=C1C(NC(=O)C1=CC=CC=C1)=CC(=C2)S(O)(=O)=O)S(O)(=O)=O ZWONWYNZSWOYQC-UHFFFAOYSA-N 0.000 description 1
- QQWUGDVOUVUTOY-UHFFFAOYSA-N 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)C(C)C QQWUGDVOUVUTOY-UHFFFAOYSA-N 0.000 description 1
- YERWMQJEYUIJBO-UHFFFAOYSA-N 5-chlorosulfonyl-2-[3-(diethylamino)-6-diethylazaniumylidenexanthen-9-yl]benzenesulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(Cl)(=O)=O)C=C1S([O-])(=O)=O YERWMQJEYUIJBO-UHFFFAOYSA-N 0.000 description 1
- AXGKYURDYTXCAG-UHFFFAOYSA-N 5-isothiocyanato-2-[2-(4-isothiocyanato-2-sulfophenyl)ethyl]benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC(N=C=S)=CC=C1CCC1=CC=C(N=C=S)C=C1S(O)(=O)=O AXGKYURDYTXCAG-UHFFFAOYSA-N 0.000 description 1
- HWQQCFPHXPNXHC-UHFFFAOYSA-N 6-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2NC1=NC(Cl)=NC(Cl)=N1 HWQQCFPHXPNXHC-UHFFFAOYSA-N 0.000 description 1
- YALJZNKPECPZAS-UHFFFAOYSA-N 7-(diethylamino)-3-(4-isothiocyanatophenyl)-4-methylchromen-2-one Chemical compound O=C1OC2=CC(N(CC)CC)=CC=C2C(C)=C1C1=CC=C(N=C=S)C=C1 YALJZNKPECPZAS-UHFFFAOYSA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000016718 Chromosome Inversion Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 241000192091 Deinococcus radiodurans Species 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000258955 Echinodermata Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100039826 G protein-regulated inducer of neurite outgrowth 1 Human genes 0.000 description 1
- 101710150822 G protein-regulated inducer of neurite outgrowth 1 Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091008121 PML-RARA Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- MTVVRWVOXZSVBW-UHFFFAOYSA-M QSY21 succinimidyl ester Chemical compound [Cl-].C1CN(S(=O)(=O)C=2C(=CC=CC=2)C2=C3C=CC(C=C3OC3=CC(=CC=C32)N2CC3=CC=CC=C3C2)=[N+]2CC3=CC=CC=C3C2)CCC1C(=O)ON1C(=O)CCC1=O MTVVRWVOXZSVBW-UHFFFAOYSA-M 0.000 description 1
- BDJDTKYGKHEMFF-UHFFFAOYSA-M QSY7 succinimidyl ester Chemical compound [Cl-].C=1C=C2C(C=3C(=CC=CC=3)S(=O)(=O)N3CCC(CC3)C(=O)ON3C(CCC3=O)=O)=C3C=C\C(=[N+](\C)C=4C=CC=CC=4)C=C3OC2=CC=1N(C)C1=CC=CC=C1 BDJDTKYGKHEMFF-UHFFFAOYSA-M 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 108091028733 RNTP Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102000042303 SPRING family Human genes 0.000 description 1
- 108091078185 SPRING family Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000204666 Thermotoga maritima Species 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 241000589501 Thermus caldophilus Species 0.000 description 1
- 241000589498 Thermus filiformis Species 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 241000193758 [Bacillus] caldotenax Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- HFCFMRYTXDINDK-WNQIDUERSA-N cabozantinib malate Chemical compound OC(=O)[C@@H](O)CC(O)=O.C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 HFCFMRYTXDINDK-WNQIDUERSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000037516 chromosome inversion disease Diseases 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- RAGZEDHHTPQLAI-UHFFFAOYSA-L disodium;2',4',5',7'-tetraiodo-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21 RAGZEDHHTPQLAI-UHFFFAOYSA-L 0.000 description 1
- KPBGWWXVWRSIAY-UHFFFAOYSA-L disodium;2',4',5',7'-tetraiodo-6-isothiocyanato-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C2=CC=C(N=C=S)C=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21 KPBGWWXVWRSIAY-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- XHXYXYGSUXANME-UHFFFAOYSA-N eosin 5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC(Br)=C(O)C(Br)=C1OC1=C(Br)C(O)=C(Br)C=C21 XHXYXYGSUXANME-UHFFFAOYSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229940107698 malachite green Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229950003968 motesanib Drugs 0.000 description 1
- RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229950008835 neratinib Drugs 0.000 description 1
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- AFAIELJLZYUNPW-UHFFFAOYSA-N pararosaniline free base Chemical compound C1=CC(N)=CC=C1C(C=1C=CC(N)=CC=1)=C1C=CC(=N)C=C1 AFAIELJLZYUNPW-UHFFFAOYSA-N 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- AJMSJNPWXJCWOK-UHFFFAOYSA-N pyren-1-yl butanoate Chemical compound C1=C2C(OC(=O)CCC)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 AJMSJNPWXJCWOK-UHFFFAOYSA-N 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- TUFFYSFVSYUHPA-UHFFFAOYSA-M rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C(C=CC(N)=C2)C2=[O+]C2=C1C=CC(N)=C2 TUFFYSFVSYUHPA-UHFFFAOYSA-M 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- COIVODZMVVUETJ-UHFFFAOYSA-N sulforhodamine 101 Chemical compound OS(=O)(=O)C1=CC(S([O-])(=O)=O)=CC=C1C1=C(C=C2C3=C4CCCN3CCC2)C4=[O+]C2=C1C=C1CCCN3CCCC2=C13 COIVODZMVVUETJ-UHFFFAOYSA-N 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
多くの癌は遺伝子融合体と関連している。おそらく最も初期に報告された例は、60年代のBML−ABLと慢性骨髄性白血病(CML)との関連である(Nowell and Hungerford (1960), J. Natl. Cancer Inst. 25:85)。それ以来、多くの異なる組織の癌について数百の遺伝子融合体が報告されている(Presner and Chinnaiyan (2009), Curr. Opin Genet. Dev. 19:82)。
(2)前記融合部位の5’である前記第1遺伝子領域の一部に特異的な第2プライマー対と、
(3)前記融合部位の3’である前記第1遺伝子領域の一部に特異的な第3プライマー対と
を含む、組成物が提供される。あるいは、前記第2及び第3プライマー対は、第2遺伝子領域に特異的であり得る。
(1)本明細書中及び上に記載された生物学的試料及び組成物を用いて、増幅反応を実施する工程と、
(2)少なくとも1つの第1プライマー対からの増幅産物の量を測定する工程(例えば、少なくとも1つの第1プライマー対に関連する標識物からのシグナルを検出することにより)と、
(3)第2プライマー対からの増幅産物量と第3プライマー対からの増幅産物の量の差の有無を検出する工程(例えば、第2及び第3プライマー対に関連する標識物のシグナルを検出及び比較することにより)と、
(4)
(i)工程(2)で測定された少なくとも1つの第1プライマー対からの増幅産物の量が、少なくとも1つの第1プライマー対からの増幅産物と対照融合遺伝子を保有しないポリヌクレオチドとの量よりも多い場合、又は
(ii)工程(3)において差異の存在が検出される場合、遺伝子融合を検出する工程と
を含む。
本発明者らは、遺伝子領域間の融合体を検出する新規な定量的及びt多重(multiplex)方法を発見した。本開示の方法は、非侵襲的に集めることができる患者試料、例えば血漿由来の循環する遊離RNA(cfRNA)の、少量を必要とするのみである。
「遺伝子融合体 (genetic fusion)」は、以前は分離されていた2つの染色体位置の結合により形成される混成染色体配列である。融合は、同じ染色体上の遺伝子(例えば、間質欠失又は染色体反転)又は異なる染色体(例えば、転座)上で起こり得る。
多くの癌関連融合遺伝子が知られており、すべての様式の癌に現れる。これらは、融合体の1つのメンバーが成長促進シグナル伝達経路に関与するキナーゼであり、他のメンバーが、上昇した又は構成的な発現又はシグナル伝達に寄与する場合に、一般的に生じる。融合部位を増幅し検出するように、及び融合部位の上流及び下流の領域を増幅及び検出するように、プライマーを設計することができるため、現在記載されている組成物及び方法は、任意の遺伝子融合を検出するために使用することができる。さらに、開示された方法は、限定された量のcfRNAを用いて実施することができるため、腫瘍の局在化及び生検が必要とされない。
遺伝子融合体について試験するための試料は任意の供給源から得ることができるが、非侵襲的に得られるもの、例えば血液又は血液画分が有利である。本方法のための試料は、気管支肺胞洗浄液又は生検組織から採取することもできる。生物学的試料から核酸を単離する方法は、例えば Sambrook に記載されているように公知であり、いくつかのキットが市販されている(例えば、RocheからのHigh Pure RNA Isolation Kit, High Pure Viral Nucleic Acid Kit, 及び MagNA Pure LC Total Nucleic Acid Isolation Kit)。
核酸増幅は、任意のプライマー依存性方法を用いて行うことができる。いくつかの実施態様において、増幅は定量的であり、その結果、所定の増幅標的の相対量又は実際の量を、増幅産物の量により決定することができる。
いくつかの実施態様において、本開示の方法を実施するための試薬及び材料がキットに含まれる。いくつかの実施態様において、キットは、試料を入手し、保存し、及び/又は調製するための成分を含む。そのような成分には、例えば無菌針及びシリンジ、EDTAで内側が被覆されたチューブ、緩衝液(例えば、核酸をマトリックスに結合させ、そしてマトリックスから溶出するため)、RNase阻害剤、及び/又はDNaseなどが含まれる。
(i)遺伝子融合体中の融合部位に特異的な少なくとも1つの第1プライマー対と、
(ii)融合部位の上流(5’)の配列の一部に特異的な第2プライマー対と、
(iii)融合部位の下流(3’)の配列の一部に特異的な第3プライマー対と、
を含む。いくつかの実施態様において、キットはさらに、陽性対照プライマー対(例えば、ハウスキーピング遺伝子由来の配列、又は試料中に存在すると予想される別の配列)、及び/又は陰性対照プライマーセット(例えば、異なる生物由来の配列のような、試験されることが期待されない試料中の配列を増幅するように設計された)を含む。少なくとも1つの第1プライマー対(i)は、遺伝子融合体の変異体を検出することができる2つ以上のプライマー対を含むことができる。いくつかの実施態様において、複数のプライマー対は、同じリバースプライマーを利用する複数のフォワードプライマー、又は同じフォワードプライマーを利用する複数のリバースプライマーを含む。
A.実施例1:血漿中のEML4−ALK融合体、及び力価測定された細胞性RNAの検出
この例では、EML4−ALK融合体を検出するための多重定量的RT−PCR法を試験した。測定可能で信頼できる結果を得るために必要な試料の量を減らすために、4つの異なるプライマーセットがシングルチューブアッセイで使用される。
この例では、細胞系及び血漿由来のRNAにおけるCCDC6−RET融合体を検出する能力について多重qRT−PCRを試験した。
Claims (23)
- 以下を含む組成物:
− 遺伝子1と遺伝子2との間の融合部位に特異的な少なくとも1つの第1プライマー対であって、前記融合部位の5’側から開始する少なくとも1つのフォワードプライマーと、前記融合部位の3’側から開始する少なくとも1つのリバースプライマーとを含む、第1プライマー対、
− 前記融合部位の5’である遺伝子1の一部に特異的な第2プライマー対、及び
− 前記融合部位の3’である遺伝子1の一部に特異的な第3プライマー対。 - 対照配列に特異的な第4のプライマーセットをさらに含む、請求項1に記載の組成物。
- 前記少なくとも1つの第1プライマー対が、少なくとも3つのプライマー対を含む、請求項1又は2に記載の組成物。
- 熱安定性DNAポリメラーゼをさらに含む、請求項1〜3のいずれか1項に記載の組成物。
- 逆転写酵素をさらに含む、請求項1〜4のいずれか1項に記載の組成物。
- 個体由来の生物学的試料をさらに含む、請求項1〜5のいずれか1項に記載の組成物。
- 前記生物学的試料が血漿由来のRNAである、請求項6に記載の組成物。
- 遺伝子1が、ALK、RET、ROS、NTRK、BRAF、ABL、及びFGFRから選択される、請求項1〜7のいずれか1項に記載の組成物。
- 遺伝子1がALKであり、遺伝子2が、EML4、KIF5B、HIP1、KLC1、及びTFGからなる群より選択される、請求項8に記載の組成物。
- 遺伝子1がRETであり、遺伝子2が、KIF5B、CCDC6、NCOA4、及びTRIM33からなる群より選択される、請求項8に記載の組成物。
- 個体由来の生物学的試料が融合遺伝子を保有するかどうかを検出するための方法であって、
− 個体由来の生物学的試料と請求項1〜5のいずれか1項に記載の組成物とを用いて増幅反応を実施する工程と、
− 前記少なくとも1つの第1プライマー対からの増幅産物の量を測定する工程と;
− 前記第2プライマー対からの増幅産物の量と前記第3プライマー対からの増幅産物の量との差の有無を検出する工程と、
− (i)工程(B)で測定された前記少なくとも1つの第1プライマー対からの増幅産物の量が、前記少なくとも1つの第1プライマー対からの増幅産物の量と融合遺伝子を保有しない対照ポリヌクレオチドの量よりも多い場合、又は
(ii)差の存在が工程(C)において検出される場合、
融合遺伝子を検出する工程と、
を含む、方法。 - 前記生物学的試料が、分離されたDNA又はRNAである、請求項11に記載の方法。
- 前記生物学的試料が個体の血漿由来のRNAである、請求項12に記載の方法。
- 遺伝子1がALK、RET、ROS、NTRK、BRAF、ABL、及びFGFRから選択される、請求項11〜13のいずれか1項に記載の方法。
- 遺伝子1がALKであり、遺伝子2がEML4、KIF5B、HIP1、KLC1、及びTFGからなる群より選択される、請求項14に記載の方法。
- 遺伝子1がRETであり、遺伝子2がKIF5B、CCDC6、NCOA4、及びTRIM33からなる群より選択される、請求項14に記載の方法。
- 前記増幅反応が、定量的逆転写ポリメラーゼ連鎖反応(qRT−PCR)を使用して実施される、請求項11〜16のいずれか1項に記載の方法。
- 個体由来の生物学的試料中の融合遺伝子を検出するためのキットであって、
− 遺伝子1と遺伝子2との間の融合部位に特異的な少なくとも1つの第1プライマー対であって、融合部位の5’側から開始する少なくとも1つのフォワードプライマーと、融合部位の3’側から開始する少なくとも1つのリバースプライマーとを含む、第1プライマー対と、
− 前記融合部位の5’である遺伝子1の一部に特異的な第2プライマー対と、
− 前記融合部位の3’である遺伝子1の一部に特異的な第3プライマー対と、
を含み、
A、B、及びCのプライマー対が、それぞれ別の容器中にあるか、又は2つ以上が単一の容器中に貯蔵される、
キット。 - 対照配列に特異的な第4のプライマーセットをさらに含み、ここで、前記第4プライマーセットは、A、B、及びCのプライマー対とは別の容器中にあるか、又は同じ容器に貯蔵される、請求項18に記載のキット。
- 熱安定性DNAポリメラーゼをさらに含む、請求項18又は19に記載のキット。
- 逆転写酵素をさらに含む、請求項18〜20のいずれか1項に記載のキット。
- 少なくとも1つの対照試料をさらに含む、請求項18〜21のいずれか1項に記載のキット。
- 前記少なくとも1つの対照試料が、融合遺伝子を保有しないDNA又はRNA、及び/又は融合遺伝子を保有するDNA又はRNAを含む、請求項22に記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562149381P | 2015-04-17 | 2015-04-17 | |
US62/149,381 | 2015-04-17 | ||
PCT/EP2016/058324 WO2016166269A1 (en) | 2015-04-17 | 2016-04-15 | Multiplex pcr to detect gene fusions |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018514202A true JP2018514202A (ja) | 2018-06-07 |
JP6856544B2 JP6856544B2 (ja) | 2021-04-07 |
Family
ID=55794958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017554014A Active JP6856544B2 (ja) | 2015-04-17 | 2016-04-15 | 遺伝子融合体を検出するための多重pcr |
Country Status (7)
Country | Link |
---|---|
US (1) | US10253349B2 (ja) |
EP (1) | EP3283645B1 (ja) |
JP (1) | JP6856544B2 (ja) |
CN (1) | CN107532209A (ja) |
CA (1) | CA2982870C (ja) |
ES (1) | ES2728437T3 (ja) |
WO (1) | WO2016166269A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3464625A1 (en) | 2016-06-01 | 2019-04-10 | F. Hoffmann-La Roche AG | Novel mutations in anaplastic lymphoma kinase predicting response to alk inhibitor therapy in lung cancer patients |
EP3622071A4 (en) * | 2017-05-10 | 2020-05-20 | Nantomics, LLC | CIRCULATING RNA FOR DETECTING, PREDICTING AND MONITORING CANCER |
AU2018277210B2 (en) * | 2017-05-31 | 2024-03-28 | F. Hoffmann-La Roche Ag | Multiplex PCR detection of ALK, RET, and ROS fusions |
CN107385042B (zh) * | 2017-07-28 | 2021-01-01 | 广州永诺健康科技有限公司 | 一种锚定巢式多重pcr联合高通量测序检测基因融合的多重pcr引物和方法 |
US11821043B2 (en) | 2017-08-17 | 2023-11-21 | Nantomics Llc | Dynamic changes in circulating free RNA of neural tumors |
CN107574232A (zh) * | 2017-08-21 | 2018-01-12 | 上海派森诺生物科技股份有限公司 | 人eml4‑alk融合基因检测方法 |
CN109929920A (zh) * | 2017-12-19 | 2019-06-25 | 李劲风 | 用于检测基因融合的多重pcr方法、试剂盒和组合物 |
WO2019133391A1 (en) * | 2017-12-20 | 2019-07-04 | Nantomics, Llc | Using cfrna for diagnosing minimal residual disease |
CN108728538B (zh) * | 2018-05-31 | 2021-09-28 | 广州迈景基因医学科技有限公司 | Alk基因融合检测引物、方法及试剂盒 |
TW202122590A (zh) * | 2019-08-28 | 2021-06-16 | 行動基因生技股份有限公司 | 檢測ntrk基因融合的套組及方法 |
CN110982903A (zh) * | 2019-12-31 | 2020-04-10 | 中山大学达安基因股份有限公司 | 多重检测alk基因突变的试剂盒及方法 |
CN114075602A (zh) * | 2020-08-18 | 2022-02-22 | 派德洛格(天津)生物科技有限公司 | 检测人ccdc6-ret融合基因的探针、试剂、试剂盒、检测方法及应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100304390A1 (en) * | 2009-05-26 | 2010-12-02 | Quest Diagnostics Investments Incorporated | Methods for detecting gene dysregulations |
JP2012100626A (ja) * | 2010-11-12 | 2012-05-31 | Srl Inc | 転座遺伝子の検出方法 |
JP2012526563A (ja) * | 2009-05-15 | 2012-11-01 | インサイト ジェネティクス インコーポレイテッド | 癌を診断および治療するためのalkの融合に関する方法および組成物 |
JPWO2011043220A1 (ja) * | 2009-10-06 | 2013-03-04 | 富士レビオ株式会社 | 融合遺伝子の測定方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5455170A (en) | 1986-08-22 | 1995-10-03 | Hoffmann-La Roche Inc. | Mutated thermostable nucleic acid polymerase enzyme from Thermus species Z05 |
US20040022764A1 (en) * | 2002-07-31 | 2004-02-05 | Hanan Polansky | Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease |
EP1398375A1 (en) * | 2002-09-13 | 2004-03-17 | Cosmix Molecular Biologicals GmbH | Recombination process for recombining fragments of variant polynucleotides |
-
2016
- 2016-04-15 EP EP16717345.9A patent/EP3283645B1/en active Active
- 2016-04-15 US US15/130,486 patent/US10253349B2/en active Active
- 2016-04-15 ES ES16717345T patent/ES2728437T3/es active Active
- 2016-04-15 JP JP2017554014A patent/JP6856544B2/ja active Active
- 2016-04-15 CN CN201680022112.4A patent/CN107532209A/zh active Pending
- 2016-04-15 CA CA2982870A patent/CA2982870C/en active Active
- 2016-04-15 WO PCT/EP2016/058324 patent/WO2016166269A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012526563A (ja) * | 2009-05-15 | 2012-11-01 | インサイト ジェネティクス インコーポレイテッド | 癌を診断および治療するためのalkの融合に関する方法および組成物 |
US20100304390A1 (en) * | 2009-05-26 | 2010-12-02 | Quest Diagnostics Investments Incorporated | Methods for detecting gene dysregulations |
JPWO2011043220A1 (ja) * | 2009-10-06 | 2013-03-04 | 富士レビオ株式会社 | 融合遺伝子の測定方法 |
JP2012100626A (ja) * | 2010-11-12 | 2012-05-31 | Srl Inc | 転座遺伝子の検出方法 |
Non-Patent Citations (2)
Title |
---|
GRUBER, K. ET AL.: "Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens U", JOURNAL OF THORACIC ONCOLOGY, vol. 9, no. 3, JPN6020003249, March 2014 (2014-03-01), pages 307 - 315, XP008180579, ISSN: 0004355013, DOI: 10.1097/JTO.0000000000000068 * |
新井 康仁: "固形がんにおける融合遺伝子の解析と治療への展開", 医学のあゆみ, vol. 249, no. 10, JPN6020003252, 7 June 2014 (2014-06-07), pages 1107 - 1112, ISSN: 0004355014 * |
Also Published As
Publication number | Publication date |
---|---|
ES2728437T3 (es) | 2019-10-24 |
EP3283645B1 (en) | 2019-03-27 |
CA2982870A1 (en) | 2016-10-20 |
US20160304937A1 (en) | 2016-10-20 |
JP6856544B2 (ja) | 2021-04-07 |
WO2016166269A1 (en) | 2016-10-20 |
CA2982870C (en) | 2021-08-10 |
CN107532209A (zh) | 2018-01-02 |
EP3283645A1 (en) | 2018-02-21 |
US10253349B2 (en) | 2019-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6856544B2 (ja) | 遺伝子融合体を検出するための多重pcr | |
US11913079B2 (en) | Detection of gene fusions by intragenic differential expression (ide) using average cycle thresholds | |
US20230121541A1 (en) | Multiplex pcr detection of alk, ret, and ros fusions | |
Miyamae et al. | Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissue | |
US11275088B2 (en) | BCR-ABL variants | |
US11261482B2 (en) | Composition for detecting epidermal cell growth factor receptor gene mutation, and kit comprising same | |
JP6153758B2 (ja) | 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用キット | |
CN104395468A (zh) | 检测hla-a*24:02的方法及检测试剂盒 | |
EP2496710B1 (en) | Determination of 17q gain in neuroblastoma patients by analysis of circulating dna | |
JP2023178670A (ja) | 検出方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190401 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200122 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200501 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200929 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201223 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210216 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210318 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6856544 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |